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Matrix gla proteinValvular and vascular calciﬁcation are common causes of cardiovascular morbidity and mortality. Developing
effective treatments requires understanding the molecular underpinnings of these processes. Shear stress is
thought to play a role in inhibiting calciﬁcation. Furthermore, NOTCH1 regulates vascular and valvular endothe-
lium, and humanmutations in NOTCH1 can cause calciﬁc aortic valve disease. Here, we determined the genome-
wide impact of altering shear stress andNOTCH signaling on human aortic valve endothelium.mRNA-sequencing
of primary human aortic valve endothelial cells (HAVECs) with or without knockdown of NOTCH1, in the pres-
ence or absence of shear stress, revealed NOTCH1-dependency of the atherosclerosis-related gene connexin 40
(GJA5), and numerous repressors of endochondral ossiﬁcation. Among these, matrix gla protein (MGP) is highly
expressed in aortic valve and vasculature, and inhibits soft tissue calciﬁcation by sequestering bone morphoge-
netic proteins (BMPs). Altering NOTCH1 levels affected MGP mRNA and protein in HAVECs. Furthermore, shear
stress activated NOTCH signaling and MGP in a NOTCH1-dependent manner. NOTCH1 positively regulated
endothelialMGP in vivo through speciﬁc binding motifs upstream ofMGP. Our studies suggest that shear stress
activates NOTCH1 in primary human aortic valve endothelial cells leading to downregulation of osteoblast-like
gene networks that play a role in tissue calciﬁcation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Calciﬁc aortic valve disease (CAVD) affects roughly 2% of the U.S.
population and is the leading cause for valve replacement [1–3]. This
incidence climbs in an age-dependent fashion, with 13% of individuals
between 75 and 85 years of age suffering from CAVD [3–6]. In addition,
25% of patients born with congenitally bicuspid aortic valves, rather
than the normal three-leaﬂet aortic valve, develop valve calciﬁcation
as they age, suggesting a common genetic link between bicuspid aortic
valves and a predisposition to calciﬁcation [7–10]. While valve replace-
ment can successfully address the stenosis and regurgitation associated
with valve disease, the procedure is invasive, expensive, and carries sig-
niﬁcantmorbidity. In addition, 50% of individuals with CAVD also devel-
op vascular stenosis and calciﬁcation, suggesting amechanistic link [11].
The late onset and progressive nature of CAVD make it an ideal candi-
date for therapeutic intervention to slow progression of the calciﬁca-
tion; however, there are currently no such therapies available. A
prerequisite to developing effective therapies is a better understanding
of the molecular events that lead to aortic valve calciﬁcation.
Aortic valve calciﬁcation is epidemiologically associated with multi-
ple risk factors including age, gender, height, hypertension, smoking,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stenosis include inﬂammation, extracellular matrix remodeling includ-
ing ﬁbrosis, valve thickening, and angiogenesis. Ultimately, aberrant
activation of osteoblast-like gene networks that lead to calciﬁcation
are observed in the valve, which is very similar to the osteoblastic
gene expression reported in vascular calciﬁcation [3,13]. In both set-
tings, hemodynamic shear stress has been implicated in preventing
the progression of calciﬁcation [10,14]. Laminar shear stress seems to
be a protective anti-calciﬁcation force that is sensed by the endothelial
lining of the arterial system, while regions of disturbed ﬂow are more
likely to calcify. Turbulent or oscillatory blood ﬂow is typically observed
at vascular bifurcations and on the aortic side of aortic valve leaﬂets,
coinciding with sites of calciﬁcation [11,15].
While there are many factors associated with calciﬁcation, a hall-
mark of the disease process is the conversion of interstitial cells to
osteoblast-like cells. The aortic valve consists of endothelial cells, mes-
enchymal interstitial cells and extracellularmatrix components, includ-
ing collagen, elastin and glycosaminoglycans, that provide strength and
ﬂexibility [16]. During valve calciﬁcation, interstitial cells of unknown
origin begin to expressα-smooth muscle actin and subsequently trans-
form into osteoblast-like cells. Recent evidence suggests that these
calcifying cells may originate from the valve endothelium [17]. These
cells express the osteoblast-specifying transcription factor, RUNX2,
and other calciﬁcation promoting proteins like ALP (alkaline phospha-
tase), IBSP (bone sialoprotein) and SPARC (osteonectin) [3,13]. While
alterations of many cellular pathways, including TGFβ, NOTCH, and
WNT signaling, result in the activation of RUNX2 in vitro, the molecular
mediators of this activation are largely unknown [3].
We previously reported two familieswith aortic valve disease attrib-
uted to heterozygous non-sense mutations in NOTCH1 that suffered
from severe, early calciﬁcation of the aortic valve and presence of a
bicuspid aortic valve in many subjects [5]. These mutations result in
truncated NOTCH1 mRNA transcripts that are predicted to undergo
nonsense-mediated decay, suggesting haploinsufﬁciency of NOTCH1
[5]. In addition, multiple mouse models with decreased NOTCH signal-
ing have shown increases in valve calciﬁcation [18,19]. NOTCH1 is a
transmembrane protein that is cleaved upon binding to its ligands
(Delta-like 1,3,4 and Jagged 1,2), which are expressed on neighboring
cells [1,2]. Upon cleavage, the intracellular domain translocates to the
nucleus and binds to the DNA-binding adaptor protein CSL [1]. Subse-
quently, co-activatorsMAMLand histone acetyl transferases are recruit-
ed to the CSL complex, resulting in chromatin modiﬁcation and target
gene activation [1]. A candidate approach revealed that decreased
in vitro expression of the NOTCH targets HEY1 and HEY2 in COS7 cells
resulted in de-repression of RUNX2 [5]. However, as a transcription
factor, NOTCH1 is likely to affect numerous target genes in vivo.
As part of our effort to understand the intersection between NOTCH
signaling and shear stress in human valve disease, we recently reported
a multi-omics analysis of human induced pluripotent stem cell (iPSC)-
derived endothelial cells [20]. Comparison of control and NOTCH1
haploinsufﬁcient iPSC-derived endothelial cells demonstrated that
shear stress protects human endothelial cells by suppressing osteogene-
sis and inﬂammation in a processmediated by NOTCH1. Speciﬁcally, het-
erozygous nonsense mutations in NOTCH1 that cause aortic valve
calciﬁcation altered H3K27ac at NOTCH1-bound enhancers, leading to
gene expression changes indicative of valve calciﬁcation. The depth of
those epigenetic studies was enabled by the generation of abundant en-
dothelial cells from human iPSC cells. Yet, it remained to be determined
whether iPSC-derived endothelial cells accurately model gene networks
underlying functional primary human aortic valve endothelium.
Here, we address the role of NOTCH1 and shear stress in primary
human aortic valve tissue. We show that many genes within the endo-
chondral ossiﬁcation pathway are negatively regulated by NOTCH1 in a
shear stress-dependent manner in primary human aortic valve endo-
thelial cells, determined by RNA-sequencing (RNA-seq). Furthermore,
ChIP-seq of the NOTCH1 intracellular domain (NICD) from theseprimary cells identiﬁed potential direct targets of NOTCH1 that are im-
portant for repression of calciﬁcation. In addition to negatively regulat-
ing osteoblastic gene networks in primary HAVECs, we found NOTCH1
positively regulates the secreted matrix gla protein (MGP), which is
known to sequester BMP and calciumand inhibit soft tissue calciﬁcation
in the vasculature and aortic valve [21]. These ﬁndings support our
studies performed in human iPSC-derived endothelial cells and
may provide novel targets for therapeutic intervention in CAVD [20].
2. Materials and methods
2.1. Primary cell culture
Human Aortic Endothelial cells (HAECs) (Sciencell, San Diego, CA)
and Human Aortic Valve Endothelial cells (HAVECs) were placed on
plates coated with 10 μg/mL ﬁbronectin from bovine plasma (Sigma,
St Louis, MO) and grown in endothelial cell media (ECM) (Sciencell)
at 5% CO2. Media was changed every other day and cells were passaged
with 0.05% Trypsin EDTA when conﬂuent. All experiments were
performed with cells with fewer than 8 passages. Cells were cultured
in unidirectional pulsatile shear stress conditions using μSlide I 0.8 Luer
channel slides and ﬂow kit (Ibidi, Verona, WI) and a L/S® Modular
brushless digital dispensing drive peristaltic pump with 6-roller
cartridge pump head (Cole Parmer, Vernon Hills, IL). Cells in shear
stress conditions modeling laminar ﬂow were exposed to media ﬂow
at 15 dyn/cm2 and cells in the static condition were grown in well
plates.While only one ﬂow rate was used, multiple ﬂow rate conditions
(i.e., low vs. high) may uncover evenmore gene expression differences.
2.2. Isolating valve cells
Aortic valves were obtained from patients undergoing heart–lung
transplants for pulmonary hypertension according to the IRB at Stanford
and UCSF. The valves were classiﬁed as “normal” by the transplant sur-
geon andneither patient had pre-existing pulmonary disease from child-
hood. Leaﬂetswere removed from the discarded hearts andplaced on ice
in PBS. One leaﬂet was divided between Trizol reagent and RIPA buffer
for later RNA and protein studies. One half of a leaﬂetwasﬁxed in forma-
lin for parafﬁn embedding and sectioning and the remaining leaﬂet
pieces were processed for live cell isolation. The valves were rinsed ﬁve
times in ice cold PBS and then digested in 2.5 mg/ml collagenase type
IV (C5138, Sigma, St. Louis, MO) in M199 media (Lonza Biosciences,
Walkersville, MD) at 37 °C for 30 min. The valve tissue was vortexed to
remove valve endothelial cells, the supernatant was removed and spun
at 500 x g for 2 min, and endothelial cells were then plated in ECM on
ﬁbronectin. This method results in an endothelial cell mixture that
includes endothelial cells from both sides of the valve, which have
been shown to have differential gene and protein expression levels [5,
6]. The remaining valve tissue was digested further with 0.8 mg/ml
collagenase in M199 for 3 h at 37 °C with vortexing every 30 min. The
tissue was vortexed and pipetted repeatedly to break up the tissue
mass and then spun at 500 x g for 2 min. The supernatant containing
freed cells was transferred to a new tube and spun down at 1100 x g
for 8 min at 4 °C. The cells were resuspended in M199 containing 10%
heat inactivated FBS and 1X pen/strep, and plated onto two t75s. After
3 to 4 days, endothelial cells were puriﬁed using anti-CD31 labeled
magnetic beads (Miltenyi Biotec, Auburn, CA). To check cell type purity,
cells were stained with mouse anti-human CD31-488 and anti-human
CD144-PE conjugated antibodies (BD Biosciences) and checked by
ﬂuorescence activated cell analysis on an LSR II (BD Biosciences,
San Jose, CA).
2.3. siRNA delivery
siRNAs were delivered into endothelial cells using RNAiMax (Life
Technologies, Carlsbad, CA). The siRNAs used were NOTCH1 siRNA
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(Ambion/Life Technologies). Endothelial cell media was changed to
optimem with no supplements (Gibco/Life Technologies), and siRNA/
RNAiMax was added for 4 h. Then, the media was changed to full ECM
and the cells were harvested for analysis 48 h later.
2.4. DAPT treatment
For gene expression experiments, experimental cells were treated
with 5 μM DAPT (Sigma) in DMSO and control cells were treated with
an equivalent amount of DMSO. Cells were harvested in Trizol reagent
48 h after addition of DAPT. For Western blots, endothelial cells
were treated for 48 h in DMSO or DAPT and then trypsinized,
washed with PBS, and re-plated for 96 h before harvesting in RIPA
buffer (Sigma, St. Louis, MO) + 1X Complete Mini protease inhibitors
(Roche, Madison, WI).
2.5. RNA-seq and analysis pipeline
RNA from HAVECs from each condition was puriﬁed using TRIzol
extraction followed by RNeasy MinElute Cleanup Kit with column
DNAse digestion (Qiagen, Valencia, CA). Then, RNA from the two biolog-
ical replicates was pooled into one sample per condition prior to library
generation. 50 ng of RNAwas used with the Ovation® RNA-Seq System
(7100-08) (NuGEN, San Carlos, CA) and manufacturer's protocol to
synthesize and SPIA amplify cDNA, which was then sheared with a
covaris S-series. After end repair, puriﬁcation andP1 P2 adaptor ligation,
templated beads were generated with the EZ beads system, and librar-
ies were then paired end sequenced (50 bp forward, 35 bp reverse) on a
SOLiD4 DNA sequencing system (Life Technologies). RNA-seq reads were
aligned to the human hg19 genome using TopHat [22]. TopHat was
supplied with GTF-format annotation of known exon positions. Novel
exon discovery was disallowed—only exons and splice junctions that
were already present in the annotation were included. Duplicate reads
(reads mapping to the exact same start/stop position) were removed
using the Picard tool MarkDuplicates (http://picard.sourceforge.net/).
Secondary mapping locations were discarded. For each read, only the
top alignment was retained. For paired-end reads, any “singleton” reads
(where both ends did not map successfully) were discarded. Sequencing
depth for the four libraries ranged from 48.4 to 63.9 million unique
aligned reads. Cufﬂinks was used to obtain a reads-per-gene total and
provide normalized expression levels, reported as RPKM (reads mapped
to a gene per thousand bases of the gene, per million mapped reads)
[23]. Differentially expressed genes were identiﬁed using Cuffdiff, part
of the Cufﬂinks suite. Only genes with RPKMs N1 and CuffDiff output of
“OK” were included in subsequent analysis. Relative expression levels
for heatmaps were normalized to the control siRNA, and no ﬂow condi-
tion and values were transformed to a log base 2 scale. UCSC Genome
Browser trackswere generated usingwiggle tracks and indicate the num-
ber of fragments that mapped to a particular locus. RNA-seq data are
available from Gene Expression Omnibus (accession numbers GSE47157
& GSE47160).
2.6. ChIP-seq and ChIP-qRT-PCR
ChIP-seq was performed as described [3,8,12]. Brieﬂy, 2.5 million
HAVECs were infected with either Luciferase-myc tag or NICD1-myc
tag lentivirus and ﬁxed with formaldehyde after 48–72 h. All myc tag
ChIPs were donewith a Goat polyclonal toMyc tag-ChIP grade antibody
(ab9132, Abcam, Cambridge, MA). ChIPs were done in triplicate with
Protein G magnetic beads and then pooled for subsequent ChIP-seq
library preparation with the standard Illumina ChIP-seq library proto-
col. High-throughput sequencing was performed on an Illumina GAIIxs
machine. Tagsweremappedback to the genomeusing the bowtie align-
er [10,21] and ChIP tag densities were calculated using bedops [11,24].
Peaks in ChIP signal were identiﬁed using SPP with an enrichmentscore cutoff of 10, based on known targets of NOTCH1 [3,12,25].
Genome feature enrichment analysis was implemented in perl and R,
utilizing bedops in conjunction with Ensemble annotations [3,13,26].
Custom Taqman probes (Life Technologies) (Integrated DNA Technolo-
gies, Coralville, IA)were designed to verify selectedNICD binding sites via
qRT-PCR. Speciﬁc probe sequences are provided in supplemental data.
ChIP-seq data are available from Gene Expression Omnibus (accession
number GSE47152).
2.7. Gene ontology and pathway analysis
Individual gene expression RPKMs were used to generate relative
differential expression values. Only genes with at least 2‐fold change
in expression were considered for further analysis. Ensemble gene an-
notations were combined with ChIP-seq to identify the largest peak
within 20 kb up or downstream of each gene transcriptional start site.
We chose to search within 20 kb of the TSS since the majority of
NOTCH1 peaks occurred within this range. Patterns of differential
gene expression combined with ChIP peak scores were then used to
compile gene lists. GO Elite and GenMAPP-CS were used to predict GO
terms and pathways overrepresented in the gene sets [7,9]. GO Elite
was run with 2000 ORA permutations, Z-score cutoff of 1.96, permuted
P-value cutoff of 0.05, and minimum of 3 genes changed per term.
2.8. Electrophoretic mobility shift assays (EMSAs)
DNAbinding assayswere carried out as previously described [16,27].
Oligos were annealed, labeled with 32P-dCTP, and gel puriﬁed on a 40%
acrylamide gel. CSL protein was generated with a TNT T7/Sp6 Coupled
Reticulocyte Lysate System (Promega, Madison,WI). Each DNA binding
reaction was performed in 40 mM KCL, 15 mM HEPES pH7.9, 1 mM
EDTA, 5 mM DTT and 5% Glycerol and then run on a 6% acrylamide gel
before ﬁlm exposure to visualize the 32P. Oligos used for the EMSA
were as follows:
HES1 Wt For, 5′-GGATTACTATTTCCCACACATCTT-3′; HES1 Wt Rev,
5′- GGTAAGATGTGTGGGAAATAGTAAT-3′; HES1 Mut For, 5′- GGAT
TACTATTAACCACACATCTTA-3′; HES1 Mut Rev, 5′- GGTAAGATGT
GTGGTTAATAGTAAT-3′; MGP WT For, 5′- GGTCCAAGGGCTTTTGGG
AACAGATTTGTGAGAAAAGAGTGAAAAG-3′; MGP WT Rev, 5′-GGCT
TTTCACTCTTTTCTCACAAATCTGTTCCCAAAAGCCCTTGGA-3′; MGP
2X Mut For, 5′- GGTCCAAGGGCTTTGTCGAACAGATTTGGTCGAAAA
GAGTGAAAAG-3′; MGP 2X Mut Rev, 5′- GGCTTTTCACTCTTTTCGAC
CAAATCTGTTCGACAAAGCCCTTGGA-3′.
MGP 1XMut For, 5′-GGTCCAAGGGCTTTTGGGAACAGATTTGTGTCAA
AAGAGTGAAAAG-3′.
MGP 1X Mut Rev, 5′-GGCTTTTCACTCTTTTGACACAAATCTGTTCCCA
AAAGCCCTTGGA-3′.
2.9. qRT-PCR
RNAwas puriﬁed fromcells in Trizol reagent and cDNAwas generated
from 1 μg of RNA using Superscript III First Strand Synthesis Supermix
(Life Technologies).
Gene expression analysis was performed by quantitative reverse
transcriptase-PCR (qRT-PCR) using standard Taq-Man primer sets
and Taqman Gene Expression Mastermix on an ABI-7900 HT (Applied
Biosystems).
2.10. Immunohistochemistry
Human aortic valves were ﬁxedwith 10% formalin overnight at 4 °C,
parafﬁn embedded, and sectioned. Valve sections were subjected to
antigen retrieval under heat and pressure for 2 min in antigen retrieval
buffer (10 mM Tris, 1 mM EDTA, and 0.05% tween). The sections were
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secondary antibody source. Primary antibodieswere diluted 1:50 in PBS
Triton (0.1%) and were incubated at 4 °C overnight. The sections were
thoroughly washed with PBS and incubated with secondary antibody
diluted in PBS triton (0.1%) 1:200 for 2 h at room temperature. Sections
were thoroughly washed in PBS, nuclei stained with DAPI or Hoescht
and sections were thenmounted under coverslips and imaged. Primary
antibodies used were NOTCH1 intracellular domain (ab8925,
Abcam), cMGP (clone G8A#1), ucMGP (clone B11#1, VitaK BV,
Maastricht, The Netherlands), and phospho-SMAD 1/5/8 (#9511,
Cell Signaling Technology, Danvers, MA). All tissue sections were
imaged on a Leica DM4000B microscope using a Leica HC plan apo
20x/0.7NA objective at room temperature. A Leica DFC310FX (PC)
Color high sensitivity camera and Leica Application Suite (LAS) imaging
software were used for image capture. The same software and camera
were used on a Leica MZ16F dissecting microscope for mouse embryo
imaging.
2.11. Lentiviral production
Expression of NICDwas achieved byOmicsLink expression construct
Lv140 (GeneCopoeia, Rockville, MD) with a CMV promoter driving
NICD1 (UniProtKB/Swiss-Prot: P46531.4, aa1769-2555 2364 bp) with
a myc tag and IRES mCherry to check the percent of cells infected. A
control lentivirus contained a Luciferase gene in place of NICD in the
same LV140 construct. Lentiviral particles were produced using the
Lenti-Pac HIV expression packaging kit (Genecopoeia) and HEK-293 t
cells.
2.12. Western blot
Western blots were performed using the Licor quantitative western
blot protocol and visualized on an Odyssey Fc (Licor, Lincoln, NE).
Antibodies used were anti-β-Actin clone AC-15 (A1978, Sigma), anti-
GAPDH (ab8245, Abcam), anti-cMGP (clone G8A#1) and anti-ucMGP
(clone B11#1, VitaK BV, Maastricht, The Netherlands).
2.13. Transgenic animals
The wildtype (Wt) 821 bpMGP putative enhancer region was TOPO
cloned into pCR2.1-TOPO vector (Life Technologies) using the following
primers: MGP-Wt-800 bp For, 5′- AATGCCATAAGGGTCCTTCC-3′; MGP-
Wt-800 bp Rev, 5′-TGAAGAAGCGAGCCACATC-3′. The pCR2.1-MGP-
821 bp enhancer region was then cut with Nhe1 (New England Biolabs,
Ipswich,MA), bluntedwith T4DNApolymerase and then cutwithNot1-
HF (New England Biolabs). The MGP-821 bp enhancer was then ligated
into the plasmid pENTR1A (Life Technologies), which was cut with
Xmn1 and Not1-HF. The pENTR1A-MGP-Wt-800 bp plasmid was cut
with BglII and SanD1 (ThermoScientiﬁc,Waltham,MA) andCold Fusion
Cloning Kit was used to introduce a double stranded oligo containing
mutations in the CSL binding sites: MGP-3XMut-800 bp for 5′-
AAGTGGTCAGGTGTAGTACAGAGATCTGGGGCAATCATTGCATGTTGG
AGTCGACGATTCCAAGGGCTTTGTCGAACAGATTTGGTCGAAAAGAG
TGAAA-3′. The MGP Wt- and 3XMut-821 bp enhancers were then
subcloned into an hsp68 lacZ-DV minimal promoter plasmid using LR
clonase (Life Technologies). These ﬁnal plasmids were cut with HindIII
and NaeI before pronuclear injection in FVB/N mice. LacZ transgenes
were detected in pups by PCR from tail biopsies (Transnetyx, Cordova,
TN). All experiments using animals were reviewed and approved by
the UCSF Institutional Animal Care and Use Committee and complied
with all institutional and federal guidelines.
2.14. Statistical analysis
All experiments were performed at least three times unless other-
wise stated. All statistical analysis was completed using GraphPadPrism software. Two-way analysis was completed with two-tailed
unpaired t tests with a 95% conﬁdence interval. Multiple comparison
tests were performed by one-way ANOVA with Tukey's multiple
comparison post-test (*P b 0.05, **P b 0.01, ***P b 0.001).
2.15. Supplemental materials
ChIP-qPCRprimers, cloning sequences, siRNA sequences and lentiviral
NICD sequence are available in the supplemental section.
3. Results
3.1. Shear stress and NOTCH1 signaling in HAVECs
Normal human aortic valve sections were stained with an antibody
speciﬁc to NOTCH1 intracellular domain (NICD) in order to identify
the cellular compartment of active NOTCH1 signaling. We observed
high expression of NICD in both the valve interstitial cells and endothe-
lial cells lining the valve (Fig. 1A). Since endothelial cells would sense
shear stress and Notch signaling is known to be critical for endothelial
cell development and homeostasis, we focused our attention on these
cells. To test the interplay between NOTCH1 signaling and shear stress
forces, primary human aortic valve endothelial cells (HAVECs) were
isolated from explanted human valves and transfected with either con-
trol or NOTCH1 speciﬁc siRNAs tomimic the decreased NOTCH1 activity
in previously reported patients [5,17]. Cells from these two conditions
were then divided into static or approximately 15 dyn/cm2 media ﬂow
(shear stress) conditions for a total of four conditions (Fig. 1B). A previ-
ous comparison of endothelial cells explanted from opposite sides of
the valve and cultured under identical shear stress conditions revealed
limited variation in gene expression between the two cell populations,
in spite of dramatic differences, in vivo [3,13,28]. This highlights
the importance of ﬂow to replicate endogenous gene expression and
was an important consideration in our experimental design. qRT-PCR
conﬁrmed that the NOTCH1 gene expression was indeed activated by
shear stress and was effectively knocked down using NOTCH1 siRNA
(Fig. 1C). In addition, the canonical NOTCH1 targets, HEY2 and HES1,
and a known shear responsive gene KLF2, were activated by shear stress
(Fig. 1C). Although HEY2 remained responsive to decreased NOTCH1 in
the shear stress condition, HES1 and KLF2 expression was not affected
byNOTCH1knockdown in the presence of ﬂow, illustrating the differen-
tial sensitivity of various Notch1 targets to both ﬂow and variations in
NOTCH1 expression.
RNA-seq was performed on RNA that was pooled from two biological
replicates for each of the four conditions to understand how shear stress
and NOTCH1 signaling may be controlling global gene transcription.
GO-Elite and GenMAPP-CS were used to identify over-represented path-
ways among the dysregulated genes with a permuted P value of b0.05.
We ﬁrst considered genes that were either activated or repressed at
least 2-fold in response to decreased NOTCH1 signaling in static condi-
tions. We found that these included genes involved in transmembrane
receptor activity, gated/substrate speciﬁc channel activity, chemokine
activity, and extracellular matrix structural constituents (Table S1).
Transmembrane receptors and chemokines are involved in recruitment
of inﬂammatory cells and ECM proteins like collagens and ﬁbulins.
These processes have been shown to play a role in the progression of
valve calciﬁcation or atherosclerosis. In addition, genes involved in
the response to steroid hormone stimulus, the acute inﬂammatory
response, and integrin mediated cell adhesion were dysregulated.
We next considered genes that were down regulated by at least 2-
fold in response to decreased NOTCH1 signaling and found that they
included genes in the NOTCH signaling pathway, blood vessel mor-
phogenesis, and regulation of BMP signaling, the most potent
bone-inducing morphogens (Table S2). Also downregulated were
gene ontologies involved with inﬂammation and immune activity,
including monocyte chemotaxis, leukocyte tethering and rolling,
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progression of atherosclerosis. Finally, genes involved in vasoconstriction,
many of which play a role in coronary artery disease, were down regulat-
ed. Conversely, genes activated in the NOTCH1 knock-down static condi-
tion included voltage gated sodium channels, ﬁbroblast growth factors,
and myosin complex genes (Table S3).
Because regions of the arterial systemwith laminar blood ﬂow seem
relatively resistant to calciﬁcation, similar to the ventricular side of the
aortic valve, we investigated genes that were activated or repressed by
at least 2-fold when exposed to ﬂow (Table S4). Many genes implicated
in activin, retinoid, and SMAD receptor binding were represented,
each involving a signaling pathway that can stimulate calciﬁcation.
Metallopeptidase activity, calcium ion binding, as well as extracellu-
lar matrix protein binding (glycosaminoglycan, collagen, and ﬁbronectin
proteins) were also affected. These processes are vital to extracellular
matrix remodeling andwhen perturbed can lead to increased ECM depo-
sition, an early step in the progression towards valve stenosis and eventu-
al calciﬁcation. Regulation of cell–cell adhesion, VEGF receptor signaling,
leukocyte proliferation, and wound healing were also positively affected
by shear stress. Other pathways affected by shear stress included GPCR
signaling, endochondral ossiﬁcation, heart development, and comple-
ment and coagulation cascades.
Finally, we investigated genes that were activated by ﬂow and were
affected by decreased NOTCH1 in HAVECs, potentially indicating direct
NOTCH1 targets as NOTCH1 is canonically viewed as a transcriptional
activator (Table S5). Gene ontological networks included receptor
binding activity such as the pro-inﬂammatory interleukin-1 receptors,Fig. 1. Activated NOTCH1 is detected in valve cells in a ﬂow dependent manner. (A) Normal h
(NICD, red). NICD was found in both endothelial (arrows) and interstitial cells (arrowhead
(F) and ventricularis layer (V), respectively. Nuclei, DAPI (blue). Scale bars indicate 100 μm. (
or NOTCH1 siRNA, then cultured in static or ﬂuid ﬂow conditions. Gene expression was com
NOTCH1, two canonical direct targets, HES1 and HEY2 and a known ﬂow responsive gene,
siRNA condition with error bars representing standard deviation. (n = 3; *, p b 0.05; ** p b 0.0as well as thrombin receptors, which are involved in platelet activation
and inﬂammatory cell recruitment after formation of vascular lesions,
eventually leading to atherosclerosis. In addition, pathways including
NOTCH signaling and VEGF signalingwere affected (Table S3). Develop-
mentally important genes involved in vascular development and skele-
tal system development were also affected by decreased NOTCH1
signaling. Immune function related gene sets were represented by
leukocyte chemotaxis and negative regulation of immune response.
All of these genes may play a role in the protective effect of shear stress
that is perturbed in the case of defective NOTCH1 signaling.
Major pathways activated by shear stress and affected by decreased
NOTCH1 signaling included heart development, complement activation
and endochondral ossiﬁcation (Table 1). The genes involved in heart
development included important valve development regulators such
as TWIST1, HEY1, HEY2, and FOXC1 [2,3]. Complementation Activation
gene members were C9, CD55, and MASP1. Most importantly from the
standpoint of calciﬁcation, the endochondral ossiﬁcation pathway
members (Figure S1) included many genes important for maintaining
non-calciﬁed regions of growing bones, known as epiphyseal plates,
including SOX6, PLAT (Tissue Plasminogen Activator), PTHrP (Parathy-
roid hormone-related protein), FGF18, and MGP (Matrix Gla Protein)
(Fig. 2, S2).
3.2. Genome-wide NOTCH1 DNA-binding in HAVECs
To determine the direct transcriptional targets of NOTCH1, we per-
formed ChIP-seq to identify genome-wide DNA occupancy of NOTCH1uman aortic valve section stained with an antibody speciﬁc to the active form of NOTCH1
s). Autoﬂuorescence (AutoFl, green) of collagen and elastin highlight the ﬁbrosa layer
B) Schematic of experimental procedure. Normal HAVECs were transfected with control
pared by qRT-PCR or mRNA-seq. (C) qRT-PCR analysis of HAVECs from four conditions.
KLF2, were analyzed. Graphs show mean gene expression relative to the static, control
1; *** p b 0.001; NS, not signiﬁcant).
Table 1
Pathways activated by shear stress in NOTCH1 dependent manner.
MAPP name # Changed # Measured # on MAPP Z score P value Gene symbols
Heart development: WP1591 8 30 44 7.03 0.000 BHLHE40, BMP2, FOXC1, GATA6, HEY1, HEY2, SHH, VEGFA
Complement activation, classical pathway: WP545 3 5 17 6.95 0.001 C9, CD55, MASP1
Endochondral ossiﬁcation: WP474 9 41 64 6.56 0.000 ALPL, FGF18, FGFR3, MGP, PLAT, PTHLH, SOX6, TGFB1, VEGFA
Complement and coagulation cascades: WP558 5 19 62 5.49 0.001 C9, F2R, MASP1, PLAT, THBD
GPCRs, class A rhodopsin-like: WP455 7 59 261 3.60 0.003 F2R, F2RL2, F2RL3, GPR173, LPAR5, OR10A4, P2RY6
Adipogenesis: WP236 7 84 131 2.51 0.037 BMP2, EGR2, GATA3, LIF, PTGIS, TGFB1, TWIST1
Genes activated by at least 2‐fold in shear stress conditions and down regulated by at least 2‐fold uponNOTCH1 knockdown in shear stress conditionswere analyzedbyGOElite to identify
potential, shear stress activated pathways that depend on NOTCH1. Signiﬁcantly enriched pathways were determined by a Z score N 1.96 and P value N 0.05.
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overcome potential limitations of existing ChIP-grade NICD antibodies
and low levels of NICD protein expression, we infected HAVECs with
a lentivirus expressing a myc-tagged NOTCH1 intracellular domain
(NICD) and used anti-myc antibodies to precipitate DNA regions
bound by NOTCH1, followed by DNA sequencing. Roughly 8500 NICD
peaks were identiﬁed and approximately 6400 genes had a signiﬁcant
NOTCH1 peak within 20 kb upstream or downstream of the transcrip-
tional start site (Table S6). Gene Ontology analysis was performed on
these 6400 potential direct gene targets of NOTCH1 to identify gene net-
works thatmaybe controlled byNOTCH1.Molecular functions potentially
targeted by NOTCH1 included transmembrane receptor phosphorylation,
T cell receptor binding, SMAD and beta-catenin binding, and extracellular
matrix binding such as integrin, glycoprotein, collagen and cadherin bind-
ing (Table S7). Enriched biological processes included wound healing,
vasculogenesis, response to ﬂuid shear stress, regulation of TGFβ 2 pro-
duction, ossiﬁcation/chondroblast differentiation, and endothelial cell
proliferation/migration.
Data from the NOTCH1 ChIP-seq and RNA-seq of control and
NOTCH1-deﬁcient cells were integrated to identify potential direct
targets of NOTCH1 in HAVECs. Based on our observation that NOTCH1
is activated by ﬂow in HAVECS (1C), we focused on genes that were
simultaneously NOTCH1-dependent and ﬂow responsive. Pattern 1
contained genes that were repressed upon Notch1 depletion that
were also activated by shear stress in a NOTCH1-dependent manner
and Pattern 2 contained genes induced by NOTCH1 depletion and
repressed by shear stress in a NOTCH1-dependent manner (Fig. 3A
and Table S8). Of the genes displaying either pattern, we focused specif-
ically on those for which our ChIP-seq identiﬁed NOTCH1 occupancy
within 20 kb of the TSS, which might indicate direct transcriptional
control by NOTCH1 (Fig. 3B). Potential targets activated both by
NOTCH1 and by shear stress in a NOTCH1-dependent manner
(Figure S6) were validated by ChIP qPCR (Figure S7) and included
genes important for maintaining non-calciﬁed bone growth plates,
repressing osteogenesis, and preventing atherosclerosis, vascular calci-
ﬁcation, and angiogenesis (Figure S2-6 and Table S9). Among them, we
identiﬁed MGP as an interesting candidate whose role in human valve
calciﬁcation has not been explored. Targeted deletion of this secreted
factor in mice causes the most severe ectopic calciﬁcation phenotype
reported in any mouse model, including calciﬁcation of epiphyseal
growth plates, the arterial system, and aortic valve within weeks of
birth [5,21]. For this reason, we investigated the regulation of MGP by
NOTCH1 in greater detail.
3.3. NOTCH1 directly regulates MGP
Localization of MGP protein expression in human aortic valves has
not been reported to date. MGP exists in an uncarboxylated (inactive)
form that can be enzymatically activated by a Vitamin K-dependent
gamma carboxylase to yield λ-carboxylated MGP (cMGP). Expression
levels of bothwere assayed via immunohistochemistry using conforma-
tion speciﬁc antibodies. Both forms of MGP were expressed in the valveendothelial and interstitial cells, though the active form seemed higher
in the endothelium and the inactive formmore prevalent in the intersti-
tial cells (Fig. 4A). Secreted MGP sequesters bone morphogenetic
protein 2 (BMP2), a protein that activates SMAD signaling leading
to phosphorylation of SMADs 1, 5 and 8 (pSMAD1/5/8). Active BMP
signaling as observed by pSMAD1/5/8 staining was present in both en-
dothelial and interstitial cells, with highest expression on the aortic side
of the valve similar to results reported in Ankeny et al. (Fig. 4A) [5,29].
qRT-PCR validation in HAVECs showed that MGP expression levels
were activated by shear stress in a NOTCH1-dependent manner
(Fig. 4B). Lentiviral over-expression of NICD1 induced higher levels of
cMGP in endothelial cells but not in interstitial cells, suggesting primary
regulation of cMGP by NOTCH1 in endothelial cells (Figs. 4C–E). In con-
trast, chemical inhibition of NOTCH1 with DAPT in static conditions de-
creased the levels of active cMGP (Figs. 4F, G). HAECs were utilized for
these analyses due to the large number of cells required for Western
blotting, which could not be obtained from cultured HAVECs. Likewise,
we were unable to analyze cMGP levels in cells treated with NOTCH1
siRNA and shear stress because the ﬂow chambers used in this study
have a very limited capacity, precluding us from applying ﬂow-
mediated shear stress to enough cells for subsequent Western analysis.
Nevertheless, these data illustrate that human endothelial cells, but not
interstitial cells, modulate cMGP levels in response to NOTCH signaling.
Gene and protein expression level changes and ChIP-seq data sug-
gested that NOTCH1 might be directly activating MGP. One signiﬁcant
NOTCH1 ChIP-seq peak identiﬁedwas 20 kb upstreamofMGP, between
MGP and its closest gene, ERP27 (Figure S8). Data from the ENCODE
project involving Human Umbilical Vein Endothelial Cells (HUVECs)
indicated that this NOTCH1 ChIP-seq peak was within a region of the
genome that displays many markers of an active regulatory region
and is predicted as a “strong enhancer” [1,30]. These include markers
of accessible open chromatin (DNAse1 hypersensitivity, FAIRE) and
H3K27ac/H3K4me1 histone marks, indicating a region bound by tran-
scription factors that displace nucleosomes [2,31]. In addition, this region
is conserved throughout vertebrate evolution from human to zebraﬁsh
and Genomic Evolutionary Rate Proﬁling (GERP) shows evolutionary
constraint for a substitutiondeﬁcit. Finally, theNICDDNAbindingpartner,
CSL, is predicted to bind to a pair of strong CSL motifs 6 bp apart and to a
third weaker site 15 bp upstream in the putative enhancer (Figure S9).
Together, these observations led us to test this region as a NOTCH-
responsive MGP enhancer.
ChIP followed by qPCR conﬁrmed that the region containing CSL
sites upstreamofMGPwas enriched for NICDprotein to a similar degree
as a canonical, validated HES1-NICD/CSL binding site (Fig. 5A). In addi-
tion, electrophoreticmobility shift assays showed that in vitro transcribed
and translated CSL protein was capable of binding a labeled DNA probe
corresponding to the potential MGP enhancer (5B). This binding could
be competed by addition of excess unlabeled oligonucleotides corre-
sponding to either the validated HES1-NICD/CSL binding site or the
potential MGP enhancer. Binding was not effectively competed by
oligonucleotides in which the CSL binding sites were mutated, demon-
strating the speciﬁcity of CSL for these sites.
Fig. 2. Expression of endochondral ossiﬁcation genes is affected by shear stress and NOTCH1 signaling. Graphs showmean gene expression relative to the static, control siRNA condition
with error bars representing standard deviation. All numbers are shown in log2 scale. (n = 3; *, p b 0.05; **, p b 0.01; ***, p b 0.001, NS, not signiﬁcant).
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ated transgenic mice containing an 821 base-pair region encompassing
the CSL sites (Wt enhancer) or with mutations of the 3 CSL sites (Mut
enhancer) combined with a minimal promoter driving LacZ (Fig. 5C).
MGP is expressed in ﬁbroblasts, smooth muscle, arterial endothelium
and chondrocytes [21]. The Wt enhancer LacZ transgenics also showed
expression within many cell types. Expression of the Wt enhancerLacZ reporter was consistent in the large vessels of the arterial system
(8 out of 13 mice), including the aorta, branching arteries, pulmonary
artery, and aortic valve, suggesting that this region could direct MGP
expression in the arterial vasculature. Mutation of the 3 CSL binding
sites abolished endothelial expression throughout the arterial sys-
tem, microvessels, and valves in all Mut enhancer transgenic mice
(n = 8) (Fig. 5C). Smooth muscle expression in the aorta was
Fig. 3. Heatmap and clustering analysis of RNA-seq and ChIP-seq from HAVECs reveals
likelyNOTCH1direct targets. (A) The expression of each genewasnormalized to the static,
control siRNA condition and then Log2 transformed. Displayed genes were selected as
matching one of two patterns reﬂecting coordinate regulation by both NOTCH1 and
shear stress: pattern 1) at least 2-fold down upon NOTCH1 siRNA knockdown in both
static andﬂow conditions, and at least 2-fold up inﬂow control siRNA condition compared
to static, or pattern 2) at least 2-fold up in NOTCH1 siRNA knockdown in both static and
ﬂow conditions, and at least 2-fold down in ﬂow control siRNA condition compared to
static. (B) ChIP-seq score shows the value for the highest ChIP peak +/−20 kb from the
transcriptional start site (TSS) of each gene. Annotated genes represent potential direct
targets of NOTCH1 based on ChIP-seq score.
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enhancer mice (3/8). Thus, in endothelial cells, NOTCH directly
and positively regulates MGP, a secreted factor that is known to
be essential for repressing the osteoblastic gene program in soft
tissues, possibly contributing to the role of NOTCH1 in preventing
calciﬁcation [1,21].
4. Discussion
This study provides genome-wide investigation of NOTCH1 and
shear stress in primary human aortic valve endothelial cells and reveals
NOTCH1-dependency of multiple ossiﬁcation-repressing gene networks
in these cells. This work supports our recent ﬁndings regarding NOTCH1
haploinsufﬁciency in human iPSC-derived endothelial cells [20] and fur-
ther implicates an important function of matrix gla protein (MGP), a se-
creted factor that is highly expressed throughout the aortic valve and
vasculature and inhibits soft tissue calciﬁcation by sequestering bone
morphogenetic proteins (BMPs) [20]. MGP was expressed highly in pri-
mary valve endothelium but was expressed very lowly in human iPSC-
derived endothelial cells [20]. Using primary HAVECs, we found that
NOTCH1 positively regulated endothelial expression of MGP both
in vitro and in vivo through a cluster of CSL binding sites upstream of
theMGP locus. Our results implicateMGP as an effector of anti-calciﬁc in-
struction byNotch1 and provide the impetus for further research into this
Notch-MGP axis as a regulator of valve calciﬁcation in vivo.
Whole transcriptome proﬁling coupled with ChIP-seq provided
evidence that gene networks similar to those responsible formaintaininga non-calciﬁed region of proliferating chondrocytes in long bones, known
as the epiphyseal or growth plate, were responsive to shear stress and af-
fected byNOTCH1dosage in primary human aortic valve endothelial cells
(Fig. 6). NOTCH1 also regulatedmultiple pathways previously implicated
in the pathology of aortic valve calciﬁcation, including chondrocyte de-
velopment, immune cell interactions, and BMP signaling. For example,
our data show that GJA5 (Connexin 40) is a direct target of NOTCH1. In-
terestingly, GJA5modulates arterial endothelial identity, is shear respon-
sive, and is activated by NOTCH over-expression [32]. Furthermore,
endothelial cell-speciﬁc knockout of GJA5 results in increased levels of
atherosclerosis in mice [33]. It is intriguing to consider that the valve en-
dothelium may act in a similar manner to the perichondral cell layer of
the growth plate, secreting cytokines to control the proliferation and dif-
ferentiation of a neighboring cell type. While disruption of the NOTCH li-
gand, JAGGED1, in the aortic valve endothelium has already been shown
to cause calciﬁc disease [19], our ongoing mouse studies will interrogate
the impact of altering other endothelial NOTCH1 signaling components
on aortic valve calciﬁcation.
In addition to the endothelial contribution, it is thought that intersti-
tial cells in calcifying valves become activated myoﬁbroblasts and then
trans-differentiate into RUNX2 positive osteoblast-like cells [3,13].
Bone Morphogenic Protein (BMP) signaling via BMP2 through the
SMAD 1/5/8 pathway is thought to activate ectopic gene expression of
the bone master regulator, RUNX2 in human valve interstitial cells
[34]. NOTCH signaling also converges on Runx2 activity through the
previously described Runx2 interacting partner, Hey1/2 [5]. Future
in vivo studies will address the interplay of NOTCH1 and BMP signaling,
including how altered endothelial NOTCH signaling impacts valve
calciﬁcation via the BMP pathway. Intriguingly, recent evidence sug-
gests that enhanced BMP signaling can induce the endothelium to
transdifferentiate into calcifying cells involved in vascular calciﬁca-
tion [17,35]. It remains to be seen if a similar mechanism holds
true in human aortic valve calciﬁcation and if NOTCH1 and/or BMP
signaling play a role in the transdifferentiation of endothelial cells
into osteoblast-like cells in the aortic valve.
It has also been reported that the endothelium can affect the osteo-
genesis of vascular smooth muscle cells undergoing calciﬁcation [8,36]
and can signal to valve interstitial cells to maintain a quiescent pheno-
type characterized by lower expression levels of smooth muscle actin
[37]. Our ﬁnding that NOTCH1 directly regulates MGP may provide
further evidence for a non-cell autonomous function of NOTCH1 in
repressing the osteogenic fate through modulation of BMP signaling.
Ongoing in vivo studies will address the role of endothelial expressed
MGP in vascular calciﬁcation. Mouse knockout models suggest MGP is
themost potent inhibitor of calciﬁcation in the arterial system and rees-
tablishment of smooth muscle MGP expression rescues the arterial
calciﬁcation phenotype of MGP−/−mice [21,38]. Rescuing endothelial
expression of MGP in the MGP knockout model may provide insight
into the cell autonomous and non-autonomous roles of endothelial
MGP.
It is worth noting that our previously reported NOTCH1+/− pa-
tients had no signs of vascular calciﬁcation. While we have shown
that altering NOTCH1 impacts the level of endothelial MGP protein
expression in endothelial cells, we have also observed that altering
NOTCH signaling does not affect MGP expression in vascular smooth
muscle cells (Figs. 4D, E and data not shown). It is possible that due to
this discrepancy, the smooth muscle compartment of the arterial sys-
tem may be able to compensate for the loss of NOTCH1. In addition,
other NOTCH receptors expressed in the vascular endothelium may
compensate for decreasedNOTCH1 signaling. This highlights the impor-
tance of future co-culture experiments to be conducted with multiple
cell types from the valve and vasculature, as well as animal models to
test the signiﬁcance of these initial ﬁndings, in vivo. These limitations
of our current study are being addressed in ongoing work using
mousemodels to evaluate the role of endothelial expressedMGP in vas-
cular calciﬁcation.
Fig. 4.MGP expression is NOTCH1 dependent. (A) Normal human aortic valve sections stained with antibodies speciﬁc to: i. cMGP, the active, carboxylated form of MGP; ii. ucMGP, the
inactive, uncarboxylated form of MGP; and iii. phosphoSMAD 1/5/8 (pSMAD1/5/8) cMGP, ucMGP and pSMAD1/5/8 (red) were found in both endothelial (arrows) and interstitial
(arrowheads) cells. Autoﬂuorescence (AutoFl, green) of collagen and elastin highlight the ﬁbrosa layer (F) and ventricularis layer (V), respectively. Nuclei, DAPI (blue). Scale bars indicate
100 μm. (B) qRT-PCR analysis of MGPmRNA expression in HAVECs under four conditions. Graph showsmean gene expression relative to the no ﬂow, no siRNA condition with error bars
representing the standard deviation. (n= 3; *, p b 0.05). (C)Western blot detecting NICD, active MGP (cMGP) and GAPDH fromHAECs infected in vitro with increasing amounts of myc-
taggedNOTCH1 intracellular domain (NICD). (D) Immunostaining forNICD (red) in culturedHumanAortic Endothelial Cells (HAEC) or HumanAortic Interstitial Cells (HAIC). (E) qRT-PCR
tomeasureMGPmRNA in control or NOTCH1-overexpressing HAICs. (F)Western blot detecting activeMGP in control or γ-secretase inhibitor (DAPT) treated HAECs. (G) Quantiﬁcation of
cMGP protein in (F) normalized to Actin. Error bars show standard deviation (n = 3; **, p b 0.01; ***, p b 0.001; NS, not signiﬁcant).
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binding sites for MGP expression in the endothelium and showed that
shear stress normally upregulates MGP. MGP must be activated by aVitamin K dependent carboxylase [39]. Interestingly, use of the widely
prescribed blood thinner, Warfarin, which inhibits Vitamin K-dependent
enzymes, was recently associated with an increased incidence of aortic
Fig. 6.Model of NOTCH1 regulation of human endothelial cell calciﬁcation. Yellow shapes indicate different classes of molecules and their sub-cellular localization. Genes in black are
regulated by shear stress and NOTCH1 signaling, while those in orange also have a signiﬁcant NOTCH1 ChIP-seq peak within 20 kb of the transcriptional start site, suggesting potential
direct transcriptional regulation by NOTCH1.
Fig. 5.NOTCH directly regulates MGP through an endothelial enhancer. (A) NICD1-myc ChIP-qPCR. Relative enrichment is shown for four sites: validated HES1 NOTCH1/CSL binding site,
validatedHES1 non-CSL binding site, predicted CSL binding siteswithin the 821 bp putativeMGP enhancer and anMGPnon-CSL site. The HES1 andMGP non-CSL binding sites are located
approximately 2 kb from the CSL binding sites. Error bars indicate standard deviation. (n = 4; *, p b 0.05). (B): EMSA showing CSL binding to putative MGP enhancer. A 46 bp oligo
corresponding to the NICD1-myc ChIP-seq peak was labeled with 32P-dCTP (MGP Probe). Incubation with in vitro transcribed and translated CSL (CSL TnT) shifted the probe (arrow).
This interaction could be competed by addition of unlabeled MGP probe (unlabeled MGP) or oligo corresponding to a validated HES1 enhancer containing CSL sites (Unlabeled HES1),
but not with unlabeled oligos in which the CSL sites were mutated (Mut), demonstrating speciﬁcity. Reticulocyte lysate (Empty TnT) caused a higher, non-speciﬁc shift. (C) Images of
whole mount or histological sections from E16.0 transgenic embryos containing the 821 bp MGP enhancer upstream of the Hsp68 minimal promoter driving LacZ with or without
mutation of the three predicted CSL binding sites. Mice containing the wildtype (Wt) enhancer had strong endothelial cell expression of LacZ (blue) in the large vessels of the arterial
system (8/13) and some weak expression in the aortic valve (arrows) (4/13 embryos). Mutation of CSL sites (Mut) abolished endothelial expression (8/8); the mutant enhancer had
weak expression in the smooth muscle layer (arrowhead) of 3/8 embryos. Sections were counterstained with Eosin (red). Aorta, Ao; branchiocephalic artery, BC; left common carotid,
LCC; aortic valve, AoV.
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an inverse relationship between high levels of dietary Vitamin K2 and
all cause mortality, coronary heart disease, and atherosclerosis [41].
Although the western diet is deﬁcient in Vitamin K2, there are no inter-
ventional studies addressing whether Vitamin K2 could prevent
onset or progression of calciﬁcation diseases [42]. However, a recent
study showed that an increase in the decarboxylated, inactive, form
of MGP was associated with an increase in vascular calciﬁcation
[43]. Based on the results of this study placed in the context of cur-
rent knowledge, future animal studies investigating this potential
relationship may be warranted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2015.04.006.
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